ENSIKLOPEDIA Cari Tekan Enter untuk memulai pencarian cepat. Kembali ke Ensiklopedia Arsip Wikipedia Indonesia Abrilumab AbrilumabMonoclonal antibody Pharmaceutical compoundAbrilumabMonoclonal antibodyType?SourceHumanTargetintegrin alpha-4 beta-7Clinical dataOther namesAMG 181ATC codenoneIdentifiersCAS Number1342290-43-0ChemSpidernoneUNIIY9UQ37XT2TKEGGD10540Chemical and physical dataFormulaC6362H9806N1686O2014S52Molar mass143803.34 g·mol−1 Abrilumab (INN;[1] development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.[2] This drug was developed by MedImmune. References ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2). ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Abrilumab, American Medical Association. vteMonoclonal antibodies for the immune systemImmune systemHuman Immunosuppression: Abrilumab Adalimumab# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Garadacimab Golimumab Ianalumab† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Nipocalimab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab Mouse Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox Chimeric Andecaliximab† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab Humanized Immunosuppressive: Apolizumab§ Aselizumab Atezolizumab Benralizumab Camrelizumab† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab‡ Epratuzumab Erlizumab Etrolizumab† Fontolizumab Frexalimab† Inebilizumab Itolizumab Lampalizumab† Letolizumab Ligelizumab† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab (+berahyaluronidase alfa) Pexelizumab Pidilizumab Plozalizumab PRO 140† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412§ Immune activation: Dostarlimab Other: Ibalizumab Chimeric + humanized Otelixizumab Rozanolixizumab Sutimlimab InterleukinHuman Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab Humanized Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab† Lebrikizumab Olokizumab† Perakizumab Risankizumab Spesolimab Tildrakizumab Veterinary Lokivetmab Inflammatory lesionsMouse Besilesomab Fanolesomab‡ Lemalesomab Sulesomab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase III This monoclonal antibody–related article is a stub. You can help Wikipedia by adding missing information.vte
